Doutor Nichires Holdings Co., Ltd. AI Stock Analysis
Want to see JP:3087 full AI Analyst Report?
Doutor Nichires Holdings Co., Ltd. (3087) AI Stock Analysis
Doutor Nichires Holdings Co., Ltd.
(TSE/TYO:3087)
The score is driven primarily by strong financial quality—especially an exceptionally conservative balance sheet—and an ongoing profitability recovery, tempered by inconsistent cash-flow conversion. Technicals add support due to a clear uptrend and positive momentum indicators, while valuation is only moderately attractive given a mid-range P/E and modest dividend yield.
Doutor Nichires Holdings Co., Ltd. (3087) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 162.83B
- Dividend Yield
- 1.60%
- Average Volume (3M)
- 158.48K
- Price to Earnings (P/E)
- 19.3
- Beta (1Y)
- 0.24
- Revenue Growth
- 7.72%
- EPS Growth
- 32.66%
- Country
- Japan
- Employees
- 2,892
- Sector
- Consumer Cyclical
- Sector Strength
- 61
- Industry
- Restaurants
Doutor Nichires Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
DOUTOR NICHIRES Holdings Co., Ltd., together with its subsidiaries, operates and manages coffee shops and restaurants in Japan. It manufactures and sells breads and pastries; roasts, processes and sells coffee; and imports, exports, purchases, and se...
How the Company Makes Money
The company makes money primarily through its food-service operations. Key revenue streams typically include (1) sales from company-operated stores, where revenue is generated directly from in-store customer purchases of beverages and food; and (2) f...
Doutor Nichires Holdings Co., Ltd. Financial Statement Overview
Summary
Strong balance sheet strength (very low leverage) and a clear earnings recovery with steady revenue growth and high gross margins support a high score. The main offsets are modest net margins and uneven cash-flow conversion, with notably weaker cash generation in 2026 versus prior years.
Income Statement
78PositiveBalance Sheet
92Very PositiveCash Flow
62Positive| Breakdown | TTM | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 159.15B | 159.15B | 148.82B | 140.63B | 126.86B | 109.36B |
| Gross Profit | 93.69B | 93.69B | 89.62B | 84.19B | 74.77B | 64.31B |
| EBITDA | 14.82B | 14.82B | 14.20B | 11.58B | 6.88B | 2.40B |
| Net Income | 7.23B | 7.23B | 6.88B | 5.49B | 3.43B | 1.22B |
Balance Sheet | ||||||
| Total Assets | 136.52B | 136.52B | 134.23B | 127.79B | 121.04B | 118.23B |
| Cash, Cash Equivalents and Short-Term Investments | 29.42B | 29.42B | 38.99B | 35.80B | 32.22B | 34.55B |
| Total Debt | 2.08B | 2.08B | 2.11B | 2.77B | 2.03B | 1.54B |
| Total Liabilities | 30.96B | 30.96B | 29.88B | 28.31B | 24.74B | 24.11B |
| Stockholders Equity | 105.18B | 105.18B | 104.00B | 99.16B | 96.02B | 93.86B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.93B | 6.49B | 7.33B | 142.00M | 10.43B |
| Operating Cash Flow | 0 | 7.02B | 12.35B | 11.79B | 5.17B | 14.64B |
| Investing Cash Flow | 0 | -10.81B | -6.23B | -4.90B | -5.59B | -4.93B |
| Financing Cash Flow | 0 | -8.42B | -2.93B | -3.37B | -1.98B | -1.50B |
Doutor Nichires Holdings Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3087, the sentiment is Positive. The current price of 3875.00 is above the 20-day moving average (MA) of 3534.25, above the 50-day MA of 3368.40, and above the 200-day MA of 2987.19, indicating a bullish trend. The MACD of 149.80 indicates Negative momentum. The RSI at 71.49 is Negative, neither overbought nor oversold. The STOCH value of 88.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3087.
Doutor Nichires Holdings Co., Ltd. Peers Comparison
Overall Rating
- JP:308778Outperform
JP:319774Outperform
JP:758172Outperform
JP:354371Outperform
JP:817969Neutral
JP:815355Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:3087 | 78Outperform | JPY 170.46B | 19.26 | ― | 1.60% | 7.72% | 32.66% |
| JP:3197 | 74Outperform | JPY 849.95B | 43.65 | 10.08% | 0.65% | 11.29% | 22.50% |
| JP:7581 | 72Outperform | JPY 418.73B | 37.85 | 8.59% | 0.41% | 17.44% | -1.16% |
| JP:3543 | 71Outperform | JPY 138.75B | 19.75 | ― | 2.06% | 13.20% | 13.76% |
| JP:8179 | 69Neutral | JPY 148.26B | 25.23 | 10.80% | 1.17% | 6.72% | 18.77% |
| Sector * | 61Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
| JP:8153 | 55Neutral | JPY 138.14B | 34.91 | ― | 0.81% | 6.32% | 10.13% |
* Consumer Cyclical Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:3087 | Doutor Nichires Holdings Co., Ltd. | 3875.00 | 1452.25 | 59.94% | |
| JP:8179 | Royal Holdings Co | 1501.00 | 199.50 | 15.33% | |
| JP:3197 | Skylark Holdings Co | 3673.00 | 562.71 | 18.09% | |
| JP:7581 | Saizeriya Co | 8600.00 | 3176.42 | 58.57% | |
| JP:3543 | KOMEDA Holdings Co., Ltd. | 2958.00 | 32.32 | 1.10% | |
| JP:8153 | MOS FOOD SERVICES, INC. | 4440.00 | 460.28 | 11.57% |
Doutor Nichires Holdings Co., Ltd. Corporate Events
Doutor Nichires Completes ¥2.6 Billion Treasury Share Buyback
Doutor Nichires Holdings has announced the completion of a share buyback conducted via the Tokyo Stock Exchange’s off-auction ToSTNeT-3 system. The move forms part of a flexible capital policy aimed at adjusting the company’s financial structure in r...
Doutor Nichires Launches Targeted Share Buyback via ToSTNeT-3
Doutor Nichires Holdings Co., Ltd. has approved a share buyback as part of a flexible capital policy designed to respond to changes in its business environment and optimize shareholder value. The board has authorized the repurchase of up to 900,000 c...
Doutor Nichires Launches Share Grant Trust to Align Employee Pay With Performance
Doutor Nichires Holdings has approved the introduction of a share grant trust known as J-ESOP-RS, designed to award company shares to employees of the parent and its subsidiaries based on individual contributions. The move links compensation more clo...
Doutor Nichires Interim Profits Beat Forecasts Amid Cost Pressures
Doutor Nichires Holdings reported that its consolidated results for the six months to August 31, 2026 exceeded prior forecasts, with net sales and all profit stages outpacing expectations. Gains were driven by continued expansion in sales through the...
Doutor Nichires Raises Interim Dividend as Earnings Outpace Plan
Doutor Nichires Holdings Co., Ltd., a TSE Prime-listed operator in Japan’s food and beverage and café retail market, generates stable earnings from its chain-style coffee shops and related services. The group’s focus on accessible café formats and di...
Doutor Nichires Posts Strong Interim Profits and Hikes Dividend Guidance
Doutor Nichires Holdings reported solid interim results for the six months to August 31, 2026, with net sales rising 7.5% year on year to ¥85.7 billion and profit attributable to owners of parent jumping 32.7% to ¥5.2 billion. Operating and ordinary...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026